LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07 2021 - 11:31AM
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage
biotechnology company focused on developing bispecific gamma delta
T cell engagers (bsTCEs) to transform the treatment of cancer,
today announced that Hans van der Vliet, M.D,. Ph.D., chief
scientific officer at LAVA, will present at the AACR-NCI-EORTC
Virtual International Conference on Molecular Targets and Cancer
Therapeutics being held October 7-10, 2021.
“Gamma delta T cells play an important role in
antitumor immunity,” said Hans van der Vliet, M.D., Ph.D. “I look
forward to sharing our platform approach to harnessing the potent
and precise antitumor properties of V9V2 T cells, along with the
preclinical data from our LAVA-051 program demonstrating an
attractive therapeutic window supportive of moving into the clinic
last quarter.”
Details of the upcoming presentation at the
AACR-NCI-EORTC conference are as follows:
Title: Bispecific gamma delta T cell engagers
for the treatment of cancer
Presenter: Hans van der Vliet, M.D., Ph.D.,
chief scientific officer, LAVA Therapeutics
Session: Plenary Session 3: Bispecific T cell
Engagers and Next-gen CAR T Therapies: Pros and Cons of These
Strategies
Session Date/Time: Fri., Oct. 8, 2021, 12:05 –
1:55 p.m. ET
Session Panel Discussion: To follow completion
of Plenary Session 3 presentations
Additional information on the AACR-NCI-EORTC
Virtual International Conference on Molecular Targets and Cancer
Therapeutic is available through the conference website at
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/
About LAVA
LAVA Therapeutics N.V. is a clinical stage
biotechnology company developing a portfolio of bispecific
gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment
of solid tumors and hematological malignancies. The company’s
innovative approach utilizes bispecific antibodies engineered to
selectively kill cancer cells via the triggering of Vγ9Vδ2 T cell
antitumor effector functions upon cross-linking to tumor associated
antigens. A Phase 1/2a clinical study evaluating LAVA-051 in
patients with certain hematological malignancies is enrolling
patients. The Company currently estimates to have data from the
Phase 1 dose escalation phase of the study in the first half of
2022 with top line clinical data from the Phase 2a expansion
cohorts expected in the second half of 2022. The Company plans to
initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in
patients with prostate cancer in the fourth quarter of 2021. For
more information, please visit www.lavatherapeutics.com.
LAVA’s Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements, including in respect of the company’s anticipated
growth and clinical developments plans, including the timing of
clinical trials. Words such as “anticipate,” “believe,” “could,”
“expect,” “should,” “plan,” “intend,” “estimate,” “potential” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements are based on LAVA’s expectations and
assumptions as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties. Actual
results may differ materially from these forward-looking
statements. Forward-looking statements contained in this press
release include, but are not limited to, statements about the
preclinical data, clinical development and scope of clinical
trials, and the potential use of our product candidates to treat
various tumor targets. Many factors may cause differences between
current expectations and actual results including unexpected safety
or efficacy data observed during preclinical trials, changes in
expected or existing competition, changes in the regulatory
environment, failure of LAVA’s collaborators to support or advance
collaborations or product candidates and unexpected litigation or
other disputes, among others. In addition, the COVID-19 pandemic
may disrupt our business and that of the third parties on which we
depend, including delaying or otherwise disrupting our clinical
trials and preclinical studies, manufacturing and supply chain, or
impairing employee productivity. LAVA assumes no obligation to
update any forward-looking statements contained herein to reflect
any change in expectations, even as new information becomes
available.
CONTACT:Catherine
Day+1-917-763-2709catherine@newdaybioconsulting.com
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2023 to Apr 2024